254 related articles for article (PubMed ID: 20543101)
1. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
2. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
4. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 expression and its effect on natural killer cells in patients with multiple sclerosis.
Su N; Shi SX; Zhu X; Borazanci A; Shi FD; Gan Y
J Neuroimmunol; 2014 Nov; 276(1-2):180-6. PubMed ID: 25218211
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation.
Hao J; Campagnolo D; Liu R; Piao W; Shi S; Hu B; Xiang R; Zhou Q; Vollmer T; Van Kaer L; La Cava A; Shi FD
Ann Neurol; 2011 Apr; 69(4):721-34. PubMed ID: 21425186
[TBL] [Abstract][Full Text] [Related]
7. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
8. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells.
Ribeiro A; Laranjeira P; Mendes S; Velada I; Leite C; Andrade P; Santos F; Henriques A; Grãos M; Cardoso CM; Martinho A; Pais M; da Silva CL; Cabral J; Trindade H; Paiva A
Stem Cell Res Ther; 2013 Oct; 4(5):125. PubMed ID: 24406104
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
Front Immunol; 2020; 11():714. PubMed ID: 32391016
[TBL] [Abstract][Full Text] [Related]
11. Low-dose IL-2 induces CD56
McQuaid SL; Loughran ST; Power PA; Maguire P; Szczygiel A; Johnson PA
Clin Exp Immunol; 2020 Jun; 200(3):228-241. PubMed ID: 31989589
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
[TBL] [Abstract][Full Text] [Related]
13. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis.
Li Z; Lim WK; Mahesh SP; Liu B; Nussenblatt RB
J Immunol; 2005 May; 174(9):5187-91. PubMed ID: 15843513
[TBL] [Abstract][Full Text] [Related]
14. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.
Jiang W; Chai NR; Maric D; Bielekova B
J Immunol; 2011 Jul; 187(2):781-90. PubMed ID: 21666061
[TBL] [Abstract][Full Text] [Related]
15. [Influence of regulatory T cells on the functioning of natural killer cells during cancer immunotherapy].
Chikileva IO; Shubina IZh; Kiselevskiĭ MV
Vestn Ross Akad Med Nauk; 2012; (4):60-4. PubMed ID: 22834330
[TBL] [Abstract][Full Text] [Related]
16. Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.
Ami K; Ohkawa T; Koike Y; Sato K; Habu Y; Iwai T; Seki S; Hiraide H
Clin Exp Immunol; 2002 Jun; 128(3):453-9. PubMed ID: 12109440
[TBL] [Abstract][Full Text] [Related]
17. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M
Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
Laroni A; Armentani E; Kerlero de Rosbo N; Ivaldi F; Marcenaro E; Sivori S; Gandhi R; Weiner HL; Moretta A; Mancardi GL; Uccelli A
J Autoimmun; 2016 Aug; 72():8-18. PubMed ID: 27157273
[TBL] [Abstract][Full Text] [Related]
19. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody.
Vignali D; Gürth CM; Pellegrini S; Sordi V; Sizzano F; Piemonti L; Monti P
Transplantation; 2016 Sep; 100(9):1853-61. PubMed ID: 27306531
[TBL] [Abstract][Full Text] [Related]
20. Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells.
Monti P; Brigatti C; Heninger AK; Scirpoli M; Bonifacio E
Am J Transplant; 2009 Dec; 9(12):2727-35. PubMed ID: 19788505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
